EDAN Connects Clinical Practice and Innovation at 2026 WHX Dubai and WHX Labs Dubai
DUBAI, UAE, Feb. 12, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ) participated in WHX Dubai (Formerly Arab Health) and WHX Labs Dubai (Formerly Medlab Middle East), presenting a comprehensive portfolio of medical solutions across multiple clinical disciplines. With an expected attendance of over 235,000 visitors at WHX Dubai and 35,000 at...
Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients
ZUG, Switzerland, Feb. 12, 2026 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors. The funding will be used to advance the company's...
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). According to the most recent Journal Citation Reports (2025), the journal has an...
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase...
WuXi Vaccines Receives Brazil’s ANVISA GMP Certification
SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish facility (DP17) in Suzhou from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The facility is providing integrated manufacturing services for...
KOALA ECO REFLECTS ON YEAR OF PURPOSE, GROWTH AS IT PLANS FOR CONTINUED SUCCESS IN 2026
SANTA BARBARA, Calif., Feb. 11, 2026 /PRNewswire/ -- Koala Eco, the mood-boosting wellness brand for cleaning, home and personal care founded by Jessica Bragdon and Paul Davidson, closed out 2025 by redefining home care, proving that products can deliver on performance, sensory experience and purpose. The Koala Eco range is...
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") for six pre-clinical small interfering RNA...
Witsbb Joins Hands with Multiple Parties to Launch New Standard in Nutrition Free from Common Allergens, Scientifically Safeguarding the Health of Allergy-Prone Infants
BEIJING, Feb. 11, 2026 /PRNewswire/ -- As the number of allergy-prone infants continues to climb globally, how to provide them with safe, nutritious, and reliable dietary support has become a pressing public health issue. Recently, at the "Scientific Care, Shared Growth" public welfare advocacy event and the consensus conference on the "Technical requirements for nutritional formula foods free from...
Akeso’s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These indications include chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with...
ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation
MADRID, Feb. 11, 2026 /PRNewswire/ -- ArisGlobal, an AI-first technology company at the forefront of Life Sciences and creator of LifeSphere®, has announced five significant new product offerings to drive cross-functional operationalization of AI. On day one of Breakthrough 2026, its annual industry event, the company unveiled XDI, its next‑generation data intelligence cortex, three...
